Aziz

Life is not a long vacation, life is a constant learning process.

[Aziz @AzizJoury]

فعلها!
أول لاعب في التاريخ يسجل في ست نسخ مختلفة من نهائيات كأس العالم
#كاس_العالم_٢٠٢٦

[Aziz @AzizJoury]

يوم كروي ماتع بمشاهدة نجوم المستديرة يسجلون الأهداف في نفس اليوم.

[Aziz @AzizJoury]

وعبر الزمان سنمضي معًا

🤍🤍💚💚
#الاهلي_بطل_النخبة2026

[Aziz @AzizJoury]

More LV dilation during VA-ECMO > more mortality
Vent the LV before dilation (multiple options to 𖣘 LV)

[Aziz @AzizJoury]

A middle aged woman presented with late RCA STEMI had one of the most catastrophic mechanical complications, Ventricular septal rupture. Choosing an appropriate mechanical circulatory support for these pts is imperative.

[Aziz @AzizJoury]

When an organization still - in late 2025- blames the COVID pandemic for its sluggish performance, it undermines public trust.

[Aziz @AzizJoury]

قبلكَ، كُنا عزيزين، لكنك يا #ولي_العهد_الأمير_محمد_بن_سلمان أعدت تعريف العزة، وجعلت #السعودية والعزة وجهان لعملة واحدة.
حفظك الله يا سيدي في حلك وترحالك 💚

[Aziz @AzizJoury]

Amyloid fibrils deposits in perimysial blood vessels and within endo- and perimysial connective tissue of skeletal muscle.
Has a feature of “pseudohypertrophy” in biceps muscle in this wATTR cardiac amyloidosis pt.
** consent obtained from my patient **
PMID: 34175153

[Aziz @AzizJoury]

Caveats:
- Retrospective work, meaning risking residual confounding
- Treatment heterogeneity: No standardized protocol for meds/tMCS
- Needs a real-time clinical utility for validation (i.e., prospective, protocol-driven studies)

Work led by @NavinKapur4 👏🏽

[Aziz @AzizJoury]

Combining machine learning (ML)-based phenotypes (I–III) with SCAI stages (A–E) improves serial risk stratification in patients with cardiogenic shock when assessed at 6-hour intervals over a 72-hour period.

I'll highlight some key findings and some caveats in this work ..

[Aziz @AzizJoury]

Key findings:
- Most changes of phenotypes occur within first 6 hr (i.e., SCAI-B pt can die in 6 hours)!
- Aim for “Golden Day of Shock” to established meds/ tMCS to reverse the course
- Adding ML phenotypes to SCAI stages improves risk stratification >> mortality differences

[Aziz @AzizJoury]

Lessons learned from DELIVER Trial:

- Dapa ↓ CV events/mortaltiy in all HFimpEF subgroups
- Patients with HFimpEF (EF ≥50%) were more ♀/older/less GDMT
- The ↓ EF, the ↑ CV Death (NS)
- Regional enrollment differed by LVEF could represent specific geographical variables

[Aziz @AzizJoury]

Among pts w CardioMEMS, either:
- PA Diastolic ≤20 mmHg
- ↑PAD then ↓ to ≤20 mmHg in 90d
experienced better survival in 2yrs

Caveats:
- Although large (~ 10K pts), but still observational
- In RCTs CardioMEMS have not shown a statically significant ↓ in overall mortality

[Aziz @AzizJoury]

Semaglutide treat frailty in Obese+HFpEF?

Caveats:
1. Used Frailty Index (FI), i.e., overestimates frailty + no incorporation of physical frailty domains
2. 2ndr analysis (STEP-HFpEF) > not adequately powered for clinical events
3. No measures of body composition + adiposity

[Aziz @AzizJoury]

The "balanced distribution" between🤍/🫘 + selective strong antagonism against aldosterone + lack of active metabolite with short half life are the recipe for potential benefits of finerenone (@Bayer) in HF across the board.

[Aziz @AzizJoury]

"Let's do IVC check to guide diuretics therapy"
#RIP
Per CAVA-ADHF-DZHK10, > 300 pts were RCTs to IVC check + clinical assessment vs. clinical assessment alone. Additional U/S evaluation of IVC did not improve decongestion treatment compared with clinical assessment alone.

[Aziz @AzizJoury]

A step forward to precision medicine.
Grant et al. used data from the ARIC study (>15K pt) to evaluate how clinical, lab, and echo factors within the PREVENT-HF model relate to preclinical HF and to determine whether these factors improve HF risk prediction.
#CardioX

[Aziz @AzizJoury]

AMR remains one of the most devastating outcomes post OHTx, yet the evidence on Dx/Rx has a huge gap. This position statement emphasizes the current understanding and outlining priorities for future research to improve patient outcomes.
#CardioX

[Aziz @AzizJoury]

In the extended 13.2-yrs f/u of DANISH trial, ICD in NICMP HFrEF did not ↓ overall mortality but did ↓ SCD [HR: 0.54; 95% CI: 0.36-0.80] in younger pts. Should continue to shy away from ICD in NICMP > 70 yrs?

#CardioX Ref: https://t.co/taRijVEH9C